JNJ-67484703

JNJ-67484703 is a humanized immunoglobulin G1 kappa (huIgG1κ) monoclonal antibody developed by Janssen Research & Development, a subsidiary of Johnson & Johnson. It is designed as an immunomodulatory therapy targeting specific pathways involved in inflammation and autoimmune responses. The drug acts as an agonist of programmed cell death protein 1 (PD‑1), aiming to modulate immune cell activity and reduce disease-associated inflammation in systemic autoimmune disorders such as atopic dermatitis, rheumatoid arthritis, Sjögren's syndrome, and ulcerative colitis[1][2][4][7]. Clinical trials have evaluated its ability to alter immune cell populations within diseased tissues and improve clinical symptoms in these conditions[5][9].

Other names

JNJ-67484703JNJ67484703JNJ 67484703JNJ-4703JNJ4703JNJ 4703